Danaher Corporation $DHR Position Raised by Welch & Forbes LLC

Welch & Forbes LLC boosted its holdings in Danaher Corporation (NYSE:DHR) by 0.6% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 694,879 shares of the conglomerate’s stock after buying an additional 4,277 shares during the quarter. Danaher accounts for about 1.7% of Welch & Forbes LLC’s investment portfolio, making the stock its 13th largest position. Welch & Forbes LLC’s holdings in Danaher were worth $137,267,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in shares of Danaher by 0.4% in the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate’s stock valued at $12,296,123,000 after buying an additional 230,966 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Danaher by 3.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock valued at $4,016,404,000 after buying an additional 612,154 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Danaher by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate’s stock valued at $1,800,614,000 after buying an additional 194,466 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after buying an additional 1,450,703 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Danaher by 4.0% in the first quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate’s stock valued at $867,168,000 after buying an additional 163,332 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 0.3%

Shares of NYSE DHR opened at $215.63 on Friday. The business has a 50 day simple moving average of $203.41 and a 200 day simple moving average of $199.54. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $258.23. The stock has a market cap of $152.31 billion, a price-to-earnings ratio of 44.46, a PEG ratio of 3.28 and a beta of 0.77. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The firm had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. During the same period in the previous year, the company earned $1.71 earnings per share. The company’s revenue was up 4.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, research analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher’s dividend payout ratio is presently 26.39%.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 2,778 shares of the business’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director owned 20,751 shares of the company’s stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms have issued reports on DHR. Barclays upped their price target on Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Evercore ISI lifted their price objective on shares of Danaher from $226.00 to $245.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Scotiabank upgraded shares of Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price objective on the stock in a research report on Friday, July 11th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Danaher from $235.00 to $250.00 and gave the stock a “buy” rating in a research report on Wednesday, October 22nd. Finally, Rothschild Redb cut shares of Danaher from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 8th. Eighteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $243.39.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.